Cytori Therapeutics (CYTX) Reports In-Line Q1 Loss of 7c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ascendiant Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
May 12, 2015 6:55 AM EDTAscendiant Capital initiated coverage on Cytori Therapeutics, Inc. (NASDAQ: CYTX) with a Buy rating and a price target of $1.25.
For an analyst ratings summary and ratings history on Cytori Therapeutics, Inc. click... More
